As we speak, a company headquartered in Norcross, Ga. has a non-invasive diagnostic test that predicts cervical cancer up to two years in advance. The procedure has been approved in most of the world, and the European Union approval was based on the U.S. test Our own FDA, however, has yet to see the light (that's a little play-on-words because the test is light activated). Sales are non-existent, except for Turkey, as the world awaits a decision from the all-encompassing FDA. Approval was just gained in Mexico, where cervical cancer is the #1 cause of death in women of child bearing age. Distribution is being set up in Canada (you would know one of the names), but all eyes wait upon one county's regulatory body while people die. Serious side effects are one thing to judge....but the absence of side effects and invasiveness should not inhibit countries who already have regulatory approvals. My observation, in the case of both companies, is that there was not enough domestic testing done to prove efficacy. The other company is now being pro-active at the distributor level. Medizone, on the other hand, sits on its hands. It still has to prove that the system works in an independent environment. The problem is NOT restless natives.
News 
Market Data 
Discover 
